• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Bonus

Quote












No they don’t. This isn’t fair. The company issued more shares to public which additionally diluted the share price. This should be corrected so all reps have equal equity across all Waves 1,2 and 3 hires.
 








anonymous said:
because that's what happens in the real world, cupcake.
Click to expand...

This is not what happens in the real world. Wave 1 got contingent offers before the drug was approved. The shares should have been earmarked to the share price at that time (2,042 shares) -or- tied to the share price on Day 1 of employment (759 shares) -or- tied to the share price on the day they were allocated (1265 shares). They did none of these things, all of them would have made more sense than what they did.

Looking at how they did it for wave 2 and 3, wave 1 should have gotten shares at the price when they accepted their first offer. So over 2,000 shares. Many companies have a multi-wave hiring, none of them have half baked equity plans, some idiot didn’t think it through. We are all pre-launch hires and they should have offered everyone the same number of shares. Those reps who accepted offers before drug approval should have received more...not less.
 




With a stock this volatile and the 3 waves being so close in timing most companies would have done a 30 days look back or calculated it based upon the grant date that was shared among all reps.
 












I wouldn’t pay you to target if you only got 1 or 2 scripts either... but, I also didn’t put my foot in my mouth talking about culture and how the company was going to do the “right thing”. GR put up or STFU, all credibility gone
 




Nice bait and switch GR. Anybody have a recording of him promising us 100% of target pay if Covid shutdowns lasted through the quarter? My employment attorney said it’d help
 
















I thought I had remembered him saying we would get 100% to target. Anybody know what the new plan is? I didn’t quite understand when he explained it. Something about trying to reward top performers and account for COVID fairly for those in places like NY while also not rewarding those who did very poorly, but maybe you can try again next quarter to make some of it back while also rewarding those who weren’t impacted by covid next quarter since they have a 30 script head start while ultimately making sure they don’t pay out $2 million in IC because ultimately we are under goal? But I’m not exactly sure
 




anonymous said:
EVERYONE heard it. Now they are backing away from it. Not a smart move for a fledgling startup with one product.
Click to expand...


For the 100th time, you and everyone else in the field are the outcome of a strategy that was solely designed to save money while "softly launching" the product, manage the budget/cashflow balance, and then be ushered out after about 12-15 months when the company is erased by a giant with their own sales people for this. Covid jacked all of the timelines, especially the dollars spent portion and initial revenue.

GR and all the rest of you were "the people similar to what a contract company would hire" - EXACT QUOTE FROM THE TOP IN A 2018 PLANNING MEETING. Get over it, giving you a job was a huge favor in their eyes, just like it was for GR, the directors (which is why more passed on the role than accepted), the managers (even higher number of "No thanks" to offers), and then all the reps. Look around, it is not very tough to identify the many issues in every direction with the "field sales team". Look at the activity of the share price with our stock, run up for them to get paid, run back down before anyone else gets paid, which is also done to get it below the needed number for the acquiring company. Collect your salary, find a new job, start over at a real company that has more than a 2 year plan where the CEO is ready for retirement after 20 years at the helm.
 




anonymous said:
For the 100th time, you and everyone else in the field are the outcome of a strategy that was solely designed to save money while "softly launching" the product, manage the budget/cashflow balance, and then be ushered out after about 12-15 months when the company is erased by a giant with their own sales people for this. Covid jacked all of the timelines, especially the dollars spent portion and initial revenue.

GR and all the rest of you were "the people similar to what a contract company would hire" - EXACT QUOTE FROM THE TOP IN A 2018 PLANNING MEETING. Get over it, giving you a job was a huge favor in their eyes, just like it was for GR, the directors (which is why more passed on the role than accepted), the managers (even higher number of "No thanks" to offers), and then all the reps. Look around, it is not very tough to identify the many issues in every direction with the "field sales team". Look at the activity of the share price with our stock, run up for them to get paid, run back down before anyone else gets paid, which is also done to get it below the needed number for the acquiring company. Collect your salary, find a new job, start over at a real company that has more than a 2 year plan where the CEO is ready for retirement after 20 years at the helm.
Click to expand...

This isn’t true at all, they told me I was the best of the best and thousands applied. They just didn’t have any wiggle room in salaries so if I wanted to negotiate they would move forward with another..... oh.... oh my...
 
















Top Bottom
Back
Quote